Llwytho...
Looking forward to new targeted treatments for chronic spontaneous urticaria
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing t...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Transl Allergy |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223554/ https://ncbi.nlm.nih.gov/pubmed/28078079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0139-2 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|